HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Supplemental Data All Versions of this Article: jnumed.108.060798v1 50/8/1324    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JNM Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Lv, Y. Articles by Fu, B. M. Search for Related Content PubMed PubMed Citation Articles by Lv, Y. Articles by Fu, B. M.

A Pharmacokinetic Model for Radioimmunotherapy Delivered Through Cerebrospinal Fluid for the Treatment of Leptomeningeal Metastases

¹ Department of Biomedical Engineering, The City College of New York, New York, New York; and ² Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York

Correspondence: For correspondence or reprints contact: Bingmei M. Fu, The City College of New York, 138th St. at Convent Ave., T-402, New York, NY 10031. E-mail: fu{at}ccny.cuny.edu

Radioimmunotherapy can effectively treat leptomeningeal metastases when radiolabeled antibodies are administered into the cerebrospinal fluid (CSF). We developed a pharmacokinetic model to evaluate the role of kinetic and transport parameters of radioimmunotherapy in maximizing the therapeutic ratio, the ratio of the area under the curve for the concentration of the bound antibodies versus time (AUC[C_IAR]), to that for unbound antibodies (AUC[C_IA]). Methods: We simplified the CSF space as a single compartment and considered the binding of antibodies to antigens on tumor cells lining the surface of the CSF space. Mass conservation was applied to set up the equations for C_IAR, C_IA, and other pharmacokinetic variables. A Runge–Kutta method was used to solve the equations. Results: This model agreed with the measured data in 10 of 14 patients in the phase I trial of intra-Ommaya radioimmunotherapy using ¹³¹I-3F8. Using this model, we predicted that increasing the affinity of antibodies to antigens greatly increases AUC(C_IAR) but not AUC(C_IA); for the same amount of isotope administered, the smaller antibody dose and the higher specific activity improves therapeutic ratio. When the isotope half-life (t_1/2-I) was 0.77 h, increasing the antibody association constant enhanced AUC(C_IAR) much more than did decreasing the dissociation constant, even if overall affinity was unchanged. When t_1/2-I reached 240 h, decreasing the dissociation constant would slightly enhance AUC(C_IAR). Other predictions were that decreasing the CSF bulk flow rate would increase AUC(C_IAR), with 3 mL/h being optimal; at the same amount of antibody administered by continuous infusion and by split administrations, compared with that by the single bolus administration, one could improve AUC(C_IAR) by up to 1.8- and 1.7-fold, respectively; and for an antibody affinity of 10^–8 M, increasing t_1/2-I from 0.77 up to 64 h could greatly enhance the therapeutic ratio. Conclusion: The strong agreement between model predictions and patient data supports the validity of the assumptions and simplifications in our model. The predictions using this model are not intuitive and need to be validated in future clinical trials. The improved therapeutic ratio by optimized kinetic and transport parameters may enhance the clinical efficacy of this new treatment modality.

Key Words: kinetic model • radioimmunotherapy • intraventricular administration • cerebrospinal fluid • ¹³¹I-3F8

COPYRIGHT © 2009 by the Society of Nuclear Medicine, Inc.

Related articles in JNM:

This Month in JNM

JNM 2009 50: 11A-12A. [Full Text]